DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nevanac (Nepafenac Ophthalmic) - Current Clinical Trials

 
 



Nevanac Related Clinical Trials

Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema [Active, not recruiting]

Nepafenac 0.3% Two Study [Completed]

Confirmatory Study Nepafenac 0.3% [Completed]

Topical Nepafenac as Supplement for Diabetic Macular Edema [Completed]

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% [Completed]

Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation [Recruiting]

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification [Completed]

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients [Completed]

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes [Completed]

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT) [Completed]

A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification [Completed]

Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification [Recruiting]

Macular Edema Incidence/Severity Reduction With Nevanac [Terminated]

Nevanac 3-Month Safety Study With QID Dosing [Completed]

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery [Recruiting]

Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema [Completed]

Nepafenac Once Daily for Macular Edema - Study 2 [Completed]

Nepafenac Once Daily for Macular Edema - Study 1 [Completed]

Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK [Completed]

Nepafenac Compared to Placebo for Ocular Pain and Inflammation [Completed]

A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief [Completed]

Topical Treatment of Uveitic Macular Edema [Not yet recruiting]

Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo [Completed]

Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification [Completed]

Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery [Completed]

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery [Completed]

Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy [Recruiting]

Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery [Completed]

Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies [Active, not recruiting]

Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery [Completed]

Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort [Recruiting]

Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery [Completed]

NSAIDs and PGE2 Levels in Vitrectomy Patients [Completed]

Dropless vs. Standard Drops Contralateral Eye Study [Recruiting]

Comparison of Pain Sensation During Single Use of Two Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) [Recruiting]

NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME) [Completed]

Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1% [Completed]

Therapeutic Variables in Cataract Surgery [Completed]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017